Headache Clinical Trials

Find Headache Clinical Trials Near You

Effectiveness of an Orally Administered and Combined Neuro-Complex & Multi Supplements in the Prevention of Migraine in Adult

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura). The main endpoint of this clinical trial is : The mean changes in migraine days per month (MDM) after 8 weeks of supplementation. Participants will: Orally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Male or female between 18 and 75 years;

• Diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura)

‣ At least 5 attacks fulfilling the criteria below

⁃ Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)

⁃ Headache has at least two of the following characteristics

• unilateral location

∙ pulsating quality

∙ moderate or severe pain intensity

∙ aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)

⁃ During headache at least one of the following:

• nausea and/or vomiting

∙ photophobia and phonophobia

⁃ Not attributed to another disorder

• Migraine frequency of at least 6 headache days per month during the last 3 months;

• Stable body mass index (BMI) between 18.5-35.0;

• Stable medication use with no significant changes in prophylactic or acute migraine treatments in the past 3 months, and willingness to maintain or reduce (if not needed) this throughout the study period;

• Willingness and ability to complete an ediary (mobile app or web based) and to follow the instruction of the study;

• Having signed an informed consent.

Locations
Other Locations
Belgium
Meclinas
RECRUITING
Mechelen
Contact Information
Primary
Ine Vercammen
ine.vercammen@meclinas.com
0032 15 79 27 97
Backup
Elisa Debien
elisa.debien@meclinas.com
0032 15 79 27 97
Time Frame
Start Date: 2025-05-15
Estimated Completion Date: 2025-12-16
Participants
Target number of participants: 120
Treatments
Experimental: Supplementation Arm - Neuro-Complex and Multi Combination
Related Therapeutic Areas
Sponsors
Collaborators: Artialis
Leads: Benfida, a department of Handi-Move

This content was sourced from clinicaltrials.gov

Similar Clinical Trials